Alterity Therapeutics Limited
PRNAF
$0.0101
$0.0065180.56%
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | 2.46M | 2.55M | 2.64M | 2.45M | 2.28M |
| Total Revenue | 2.46M | 2.55M | 2.64M | 2.45M | 2.28M |
| Cost of Revenue | 119.30K | 130.20K | 140.60K | 143.70K | 147.80K |
| Gross Profit | 2.34M | 2.42M | 2.50M | 2.31M | 2.13M |
| SG&A Expenses | 3.97M | 3.56M | 3.13M | 2.97M | 2.84M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | 38.30K | 21.10K | 3.40K | 4.20K | 5.00K |
| Total Operating Expenses | 15.99M | 15.78M | 15.51M | 13.13M | 10.82M |
| Operating Income | -13.53M | -13.23M | -12.87M | -10.68M | -8.55M |
| Income Before Tax | -13.02M | -12.80M | -12.53M | -10.31M | -8.15M |
| Income Tax Expenses | 30.40K | 30.40K | 30.40K | 15.40K | 400.00 |
| Earnings from Continuing Operations | -13.05 | -12.83 | -12.56 | -10.33 | -8.15 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -13.05M | -12.83M | -12.56M | -10.33M | -8.15M |
| EBIT | -13.53M | -13.23M | -12.87M | -10.68M | -8.55M |
| EBITDA | -13.51M | -13.21M | -12.85M | -10.66M | -8.52M |
| EPS Basic | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Normalized Basic EPS | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| EPS Diluted | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Normalized Diluted EPS | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Average Basic Shares Outstanding | 20.22B | 17.41B | 14.60B | 12.24B | 9.89B |
| Average Diluted Shares Outstanding | 20.22B | 17.41B | 14.60B | 12.24B | 9.89B |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
